---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003286"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:40:52.063088+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled

## Summary
- Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.
- Last patient completed final visit in Phase 2a RIVER trial (RCC); topline results expected Q1 2025.
- Phase 2b CORAL trial (IPF chronic cough) now ~80% enrolled after positive SSRE; topline expected H1 2025.
- SSRE analysis in Dec 2024 reaffirmed original sample size of N=160 for CORAL trial.

## SEC filing metadata
- accession: 0000950170-25-003286
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/0000950170-25-003286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/trvi-20250108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003286
- JSON: https://secwatch.observer/filing/0000950170-25-003286.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.